Premium
Carvedilol and antioxidant proteins in a type I diabetes animal model
Author(s) -
Diogo Cátia V.,
Deus Cláudia M.,
LebiedzinskaArciszewska Magdalena,
Wojtala Aleksandra,
Wieckowski Mariusz R.,
Oliveira Paulo J.
Publication year - 2017
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/eci.12696
Subject(s) - carvedilol , streptozotocin , oxidative stress , medicine , diabetic cardiomyopathy , endocrinology , antioxidant , diabetes mellitus , catalase , sod2 , pharmacology , superoxide dismutase , chemistry , heart failure , cardiomyopathy , biochemistry
Background Patients with diabetes are at a high risk of developing both micro‐ and macrovascular disease. Hyperglycaemia seems to be the main factor in the pathogenesis of diabetic cardiomyopathy, often based on increased oxidative stress. Carvedilol, a β‐adrenergic blocker, has intrinsic antioxidant properties and was previously described to be effective in the protection of cardiac mitochondria against oxidative stress. The objective of this study was to evaluate the effect of carvedilol on hyperglycaemia‐induced oxidative damage and mitochondrial abnormalities in cardiac and skeletal muscle in streptozotocin‐treated rats. Materials and methods Body mass, blood glucose, the level of protein carbonylation, caspase‐9‐ and caspase‐3‐like activities, mitochondrial proteins, the status of antioxidant defence system and stress‐related proteins were evaluated in streptozotocin vs streptozotocin + carvedilol (1 mg/kg/day)‐treated rats. Results The results showed that carvedilol decreased blood glucose in streptozotocin‐treated animals. Content of catalase in the heart and SOD 2, SOD 1 and catalase in skeletal muscle were increased by carvedilol treatment in streptozotocin‐treated animals. At this particular time point, streptozotocin‐induced hyperglycaemia did not cause caspase activation or increase in protein carbonylation status. The data showed that carvedilol increased the level of antioxidant enzymes, what may contribute to preserve cell redox balance during hyperglycaemia. We also showed here for the first time that carvedilol effects on streptozotocin‐treated rats are tissue dependent, with a more predominant effect on skeletal muscle. Conclusions Based on data showing modulation of the antioxidant network in the heart, carvedilol may be beneficial in diabetic patients without advanced disease complications, delaying their progression.